Speaker Profile
Ph.D., Dual PhD., CEO and CSO, Phinomics
Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative company transforming precision medicine by unlocking the potential of circular DNA and integrating genomics with advanced AI. With dual PhDs in Molecular Biology and Biomedical Engineering, Massa has over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fires lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships, including the Arnold O. Beckman Fellowship, and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology solutions through the Circulome Atlas, a transformative platform providing unparalleled insights into cancer etiology, progression, and therapeutic resistance.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
Gad Getz, Broad Institute
Alex Morgan, Khosla Ventures
PMWC Award Ceremony Honoree
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Keynote
• Vinod Khosla, Khosla Ventures
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Illuminating Drug Discovery: AI Models That Learn From Biology
• Erwin Estigarribia, HEADLAMP Health
Harmonizing the Data Economy: Enabling AI Across Institutions and Therapeutic Areas
• Noah Nasser, Datma
Can AI Really Create the Next Blockbuster Drug?
• James Zou, Stanford
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
Closing the Loop: AI in the Messy Middle of Drug Development
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald / MIT
Is AI the New Drug?
• Michael J. Kahana, Nia Therapeutics
